Bharat Parenter.

{
  "main_header": {
    "sid": 1002949,
    "name": "Bharat Parenter.",
    "stock_name": "Bharat Parenter.",
    "full_name": "Bharat Parenterals Ltd",
    "name_url": "stocks-analysis/bharat-parenter",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,055.00",
    "chg": 79.45,
    "chgp": "8.14%",
    "dir": 1,
    "prev_price": "975.55",
    "mcapval": "672.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 541096,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE365Y01019",
    "curr_date": "Feb 09",
    "curr_time": "",
    "bse_nse_vol": 2122,
    "exc_status": "Active",
    "traded_date": "Feb 09, 2026",
    "traded_date_str": "2026 02 09",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bharat-parenter-1002949-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bharat Parenterals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-parenterals-ltd-is-rated-strong-sell-3820368",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BharatParentera_mojoScore_3820368.png",
        "date": "2026-02-04 10:10:33",
        "description": "Bharat Parenterals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 February 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Are Bharat Parenterals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-bharat-parenterals-ltd-latest-results-good-or-bad-3813383",
        "imagepath": "",
        "date": "2026-01-31 19:28:36",
        "description": "Bharat Parenterals Ltd's latest financial results for Q3 FY26 reflect significant operational challenges. The company reported consolidated net sales of ₹65.19 crores, which represents a year-on-year decline of 9.78% from ₹72.26 crores in Q3 FY25, despite a slight quarter-on-quarter increase of 0.88% from ₹64.62 crores in Q2 FY26. This revenue contraction suggests potential issues such as market share loss, pricing pressures, or demand weaknesses in key product categories.\n\nThe consolidated net profit for the quarter was a loss of ₹4.39 crores, marking a substantial year-on-year deterioration of 162.87% compared to a loss of ₹1.67 crores in Q3 FY25. This loss indicates that the company has faced persistent difficulties in translating revenue into profitability, as it has now recorded six consecutive quarters of losses.\n\nOperating margins have also come under pressure, with the operating margin (excluding ot..."
      },
      {
        "title": "Bharat Parenterals Q3 FY26: Mounting Losses Signal Deepening Operational Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/bharat-parenterals-q3-fy26-mounting-losses-signal-deepening-operational-crisis-3812021",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatParentera_quaterlyResult_3812021.png",
        "date": "2026-01-30 20:03:58",
        "description": "Bharat Parenterals Ltd., the Gujarat-based pharmaceutical manufacturer, reported a consolidated net loss of ₹4.39 crores for Q3 FY26, marking a sharp 162.87% year-on-year deterioration from a loss of ₹1.67 crores in Q3 FY25. The quarter-on-quarter performance also worsened, with losses widening 39.28% from ₹7.23 crores in Q2 FY26. The micro-cap pharmaceutical company, with a market capitalisation of ₹755.00 crores, has now posted consecutive quarterly losses, raising serious questions about operational viability and management execution."
      },
      {
        "title": "Bharat Parenterals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-parenterals-ltd-is-rated-strong-sell-3803064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatParentera_mojoScore_3803064.png",
        "date": "2026-01-24 10:10:15",
        "description": "Bharat Parenterals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Bharat Parenterals Ltd Faces Bearish Momentum Amid Technical Downturn",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bharat-parenterals-ltd-faces-bearish-momentum-amid-technical-downturn-3795335",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatParentera_technicaldot_3795335.png",
        "date": "2026-01-20 08:05:15",
        "description": "Bharat Parenterals Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with several indicators signalling a bearish trend. The company’s stock price has declined by 4.21% on the day, closing at ₹1,151.00, down from the previous close of ₹1,201.55, reflecting growing investor caution amid mixed technical signals and deteriorating momentum."
      },
      {
        "title": "Bharat Parenterals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-parenterals-ltd-is-rated-strong-sell-3778831",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatParentera_mojoScore_3778831.png",
        "date": "2026-01-02 10:10:03",
        "description": "Bharat Parenterals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 29 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Bharat Parenter. Sees Revision in Market Assessment Amid Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-parenter-downgraded-to-strong-sell-amid-weak-fundamentals-and-risky-valuation-3765624",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BharatParenter_mojoScore_3765624.png",
        "date": "2025-12-22 10:10:18",
        "description": "Bharat Parenter., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and operational metrics. The recent changes in evaluation metrics highlight concerns across quality, valuation, financial trends, and technical outlook, underscoring the company’s current position within a competitive and volatile market environment."
      },
      {
        "title": "Bharat Parenterals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bharat-parenterals-sees-mixed-technical-signals-amid-price-momentum-shift-3761994",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BharatParentera_technicaldot_3761994.png",
        "date": "2025-12-18 08:14:27",
        "description": "Bharat Parenterals has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of market forces within the Pharmaceuticals & Biotechnology sector. Recent price movements and technical indicators suggest a transition from a predominantly bearish stance to a more mildly bearish outlook, underscoring the evolving market assessment of this micro-cap stock."
      },
      {
        "title": "Why is Bharat Parenter. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bharat-parenter-fallingrising-3749671",
        "imagepath": "",
        "date": "2025-12-06 01:41:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Bharat Parenterals has experienced a notable slide in its stock price over multiple time horizons. In the past week, the share price fell by 4.43%, contrasting sharply with the Sensex’s marginal gain of 0.01%. Over the last month, the stock declined by 10.02%, while the Sensex advanced by 2.70%. Year-to-date figures reveal a more pronounced divergence, with Bharat Parenterals down 25.06% against the Sensex’s 9.69% rise. The one-year performance further highlights the stock’s struggles, registering a 35.41% loss compared to the Sensex’s 4.83% gain. Despite these setbacks, the stock has delivered strong long-term returns, with three- and five-year gains of 179.33% and 220.28% respectively, outperforming the Sensex’s 36.41% and 90.14% ..."
      }
    ],
    "total": 388,
    "sid": "1002949",
    "stock_news_url": "https://www.marketsmojo.com/news/bharat-parenterals-1002949"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "31-Jan-2026",
      "details": "copy of newspaper advertisement for the unaudited financial results for the quarter and nine months ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Quarter And Nine Months Ended On December 31 2025.",
      "datetime": "30-Jan-2026",
      "details": "Unaudited Financial Results for the Quarter and Nine Months Ended on December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting For The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended On December 31 2025.",
      "datetime": "30-Jan-2026",
      "details": "Outcome of Board Meeting held on January 30 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bharat Parenterals Ltd has declared <strong>10%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bharat Parenterals Ltd is Rated Strong Sell

2026-02-04 10:10:33

Bharat Parenterals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Are Bharat Parenterals Ltd latest results good or bad?

2026-01-31 19:28:36

Bharat Parenterals Ltd's latest financial results for Q3 FY26 reflect significant operational challenges. The company reported consolidated net sales of ₹65.19 crores, which represents a year-on-year decline of 9.78% from ₹72.26 crores in Q3 FY25, despite a slight quarter-on-quarter increase of 0.88% from ₹64.62 crores in Q2 FY26. This revenue contraction suggests potential issues such as market share loss, pricing pressures, or demand weaknesses in key product categories. The consolidated net profit for the quarter was a loss of ₹4.39 crores, marking a substantial year-on-year deterioration of 162.87% compared to a loss of ₹1.67 crores in Q3 FY25. This loss indicates that the company has faced persistent difficulties in translating revenue into profitability, as it has now recorded six consecutive quarters of losses. Operating margins have also come under pressure, with the operating margin (excluding ot...

Read full news article

Bharat Parenterals Q3 FY26: Mounting Losses Signal Deepening Operational Crisis

2026-01-30 20:03:58

Bharat Parenterals Ltd., the Gujarat-based pharmaceutical manufacturer, reported a consolidated net loss of ₹4.39 crores for Q3 FY26, marking a sharp 162.87% year-on-year deterioration from a loss of ₹1.67 crores in Q3 FY25. The quarter-on-quarter performance also worsened, with losses widening 39.28% from ₹7.23 crores in Q2 FY26. The micro-cap pharmaceutical company, with a market capitalisation of ₹755.00 crores, has now posted consecutive quarterly losses, raising serious questions about operational viability and management execution.

Read full news article

Bharat Parenterals Ltd is Rated Strong Sell

2026-01-24 10:10:15

Bharat Parenterals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Bharat Parenterals Ltd Faces Bearish Momentum Amid Technical Downturn

2026-01-20 08:05:15

Bharat Parenterals Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with several indicators signalling a bearish trend. The company’s stock price has declined by 4.21% on the day, closing at ₹1,151.00, down from the previous close of ₹1,201.55, reflecting growing investor caution amid mixed technical signals and deteriorating momentum.

Read full news article

Bharat Parenterals Ltd is Rated Strong Sell

2026-01-02 10:10:03

Bharat Parenterals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 29 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Bharat Parenter. Sees Revision in Market Assessment Amid Challenging Fundamentals

2025-12-22 10:10:18

Bharat Parenter., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and operational metrics. The recent changes in evaluation metrics highlight concerns across quality, valuation, financial trends, and technical outlook, underscoring the company’s current position within a competitive and volatile market environment.

Read full news article

Bharat Parenterals Technical Momentum Shifts Amid Mixed Market Signals

2025-12-18 08:14:27

Bharat Parenterals has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of market forces within the Pharmaceuticals & Biotechnology sector. Recent price movements and technical indicators suggest a transition from a predominantly bearish stance to a more mildly bearish outlook, underscoring the evolving market assessment of this micro-cap stock.

Read full news article

Why is Bharat Parenter. falling/rising?

2025-12-06 01:41:55

Recent Price Movement and Market Comparison

Bharat Parenterals has experienced a notable slide in its stock price over multiple time horizons. In the past week, the share price fell by 4.43%, contrasting sharply with the Sensex’s marginal gain of 0.01%. Over the last month, the stock declined by 10.02%, while the Sensex advanced by 2.70%. Year-to-date figures reveal a more pronounced divergence, with Bharat Parenterals down 25.06% against the Sensex’s 9.69% rise. The one-year performance further highlights the stock’s struggles, registering a 35.41% loss compared to the Sensex’s 4.83% gain. Despite these setbacks, the stock has delivered strong long-term returns, with three- and five-year gains of 179.33% and 220.28% respectively, outperforming the Sensex’s 36.41% and 90.14% ...

Read full news article

View All News